Related Experiment Video

Updated: May 17, 2025

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

iPSC modification strategies to induce immune tolerance.

Zixuan Hong¹, Yun Zhao¹, Sara Pahlavan²

¹Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Clinical Stem Cell Research Center, Peking University Third Hospital, Peking University, Beijing 100191, China.

|May 16, 2025

Summary

Engineering human pluripotent stem cells (hPSCs) can overcome immune rejection in cell therapy. Strategies like immune cloaking and HLA deletion offer promising solutions for regenerative medicine, improving patient outcomes.

Area of Science:

Stem Cell Biology
Immunology
Regenerative Medicine

Background:

Human pluripotent stem cells (hPSCs) show therapeutic potential but face immune rejection challenges.
Current immunosuppressants have side effects limiting hPSC derivative applications.
Developing immune tolerance strategies is crucial for advancing stem cell therapies.

Purpose of the Study:

To review recent strategies for inducing immune tolerance in engineered stem cells.
To focus on immune cloaking techniques for hPSCs.
To discuss the safety and limitations of these novel therapeutic modalities.

Main Methods:

Gene editing for human leukocyte antigen (HLA) deletion.
Engineering immune cloaks via immune checkpoint overexpression.
Blocking immune cytotoxic pathways.
Co-transplantation with mesenchymal stem cells (MSCs).

Main Results:

HLA deletion enables allografts to evade host immune responses.
Immune cloaking strategies aim to shield stem cell grafts from immune attack.
Mesenchymal stem cells (MSCs) can confer immune privilege to engrafted cells.

Conclusions:

Engineered stem cells offer a promising path to overcome immune barriers in regenerative medicine.
Further research is needed to address the safety and limitations of these advanced therapeutic approaches.

Keywords:

HLA gene editing hPSC immune checkpoint

More Related Videos

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14⁺ Monocytes

Published on: April 11, 2025

Related Concept Videos

Special Features of Adaptive Immunity

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

Chromatin Modification in iPS Cells

Chromatin Modification in iPS Cells

Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Articles linked to this work by shared authors, journal, and citation graph.

Generation of synthetic vascular organoids via orthogonal programming of human pluripotent stem cells.

Cell regeneration (London, England)·2026

Erratum : A Novel Insight into Endothelial and Cardiac Cells Phenotype in Systemic Sclerosis Using Patient-Derived.

Cell journal·2026

Impact of a comprehensive healthy lifestyle score on a broad spectrum of cardiometabolic and related diseases and its incremental value for risk prediction based on the UK biobank database.

Journal of cardiothoracic surgery·2026

Vascularized tumor organoids as models for interpreting therapeutic response.

Vascular pharmacology·2026

Protective effects of dietary omega-3 on cardiac and hepatic function, mortality, and gene expression in broilers under high stocking density.

Scientific reports·2026

SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.

Lung cancer (Amsterdam, Netherlands)·2026

See all related articles